EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

Prakriti Gaba, Michelle L O'Donoghue iD, Jeong-Gun Park, Stephen D Wiviott iD, Dan Atar, Julia F Kuder, KyungAh Im, Sabina A Murphy, Gaetano M De Ferrari, Zbigniew A Gaciong, Kalman Toth iD, Ioanna Gouni-Berthold und 11 weitere

Circulation · 18.04.2023 · 147 (16) · 1192-1203

DOI: 10.1161/circulationaha.122.063399 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 18.04.2023. Verfasst von Prakriti Gaba und 22 weiteren Autor:innen. Beteiligte Einrichtung: Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (P.G., M.L.O., J.-G.P.,…. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction. Die Arbeit wurde bisher 178-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.

Methods

In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), 27 564 patients with stable atherosclerotic cardiovascular disease were randomized to evolocumab versus placebo, with a median follow-up of 2.2 years. In the open-label extension (FOURIER-OLE), 6635 of these patients were transitioned to open-label evolocumab regardless of initial treatment allocation in the parent trial and were followed for an additional median of 5 years. In this prespecified analysis, we examined the relationship between achieved LDL-C levels (an average of the first 2 LDL-C levels measured) in FOURIER-OLE (available in 6559 patients) and the incidence of subsequent cardiovascular and safety outcomes. We also performed sensitivity analyses evaluating cardiovascular and safety outcomes in the entire FOURIER and FOURIER-OLE patient population. Multivariable modeling was used to adjust for baseline factors associated with achieved LDL-C levels.

Results

In FOURIER-OLE, 1604 (24%), 2627 (40%), 1031 (16%), 486 (7%), and 811 (12%) patients achieved LDL-C levels of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsCardiovascular DiseasesAtherosclerosisMyocardial InfarctionStrokeHydroxymethylglutaryl-CoA Reductase InhibitorsHumansProprotein Convertase 9Cholesterol, LDLPCSK9 InhibitorsTreatment Outcome

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseasescholesterollipoproteins, LDL

Substanzen

PCSK9 protein, humanProprotein Convertase 9Anticholesteremic AgentsCholesterol, LDLPCSK9 InhibitorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (P.G., M.L.O., J.-G.P., S.D.W., J.F.K., K.I., S.A.M., R.P.G., M.S.S.).
  • Division of Medicine, University of Oslo, Norway (D.A.).
  • Department of Medical Sciences, University of Turin and Department of Cardiology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy (G.M.D.).
  • Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw, Poland (Z.A.G.).
  • 1st Department of Medicine, University of Pécs, Medical School, Hungary (K.T.).
  • University of Cologne, Center for Endocrinology, Diabetes, and Preventative Medicine, University of Cologne, Faculty of Medicine and University Hospital, Germany (I.G.-B.).

ORCID-Profile: Michelle L O'Donoghue, Stephen D Wiviott, Kalman Toth, Jose Lopez-Miranda, François Schiele, François Mach, J Antonio G López, Robert P Giugliano, Marc S Sabatine

Zitieren

APA

Gaba, P., O'Donoghue, M. L., Park, J. G., Wiviott, S. D., Atar, D., Kuder, J. F., Im, K., Murphy, S. A., De Ferrari, G. M., Gaciong, Z. A., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., Mach, F., Flores-Arredondo, J. H., López, J. A. G., Elliott-Davey, M., Wang, B., …, & Sabatine, M. S. (2023). Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation, 147(16), 1192-1203. https://doi.org/10.1161/circulationaha.122.063399

Vancouver

Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023;147(16):1192-1203. doi:10.1161/circulationaha.122.063399

BibTeX
@article{Gaba2023,
  author = {Gaba, Prakriti and O'Donoghue, Michelle L and Park, Jeong-Gun and Wiviott, Stephen D and Atar, Dan and Kuder, Julia F and Im, KyungAh and Murphy, Sabina A and De Ferrari, Gaetano M and Gaciong, Zbigniew A and Toth, Kalman and Gouni-Berthold, Ioanna and Lopez-Miranda, Jose and Schiele, François and Mach, François and Flores-Arredondo, Jose H and López, J Antonio G and Elliott-Davey, Mary and Wang, Bei and Monsalvo, Maria Laura and Abbasi, Siddique and Giugliano, Robert P and Sabatine, Marc S},
  title = {Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {16},
  pages = {1192--1203},
  doi = {10.1161/circulationaha.122.063399}
}
Kostenlos starten →